| University of British Columbia | |
|---|---|
| Location | Vancouver, British Columbia, Canada |
| Type | Public research university |
| Founded | 1908 |
| Website | UBC official site |
| Neurodegeneration Focus | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Neuroscience |
| Major Units | Djavad Mowafaghian Centre for Brain Health, Department of Psychiatry, Department of Neurology |
The University of British Columbia (UBC) is Canada's leading research university, founded in 1908. Located in Vancouver, British Columbia, UBC is a major center for neurodegenerative disease research. The Djavad Mowafaghian Centre for Brain Health, located at UBC's Vancouver campus, is one of the most comprehensive brain research centers in North America[1].
UBC was established in 1908 and has grown into one of Canada's largest research universities with over $700 million in annual research funding. The university's brain health research programs have grown substantially since the establishment of the Djavad Mowafaghian Centre for Brain Health in 2012.
The Djavad Mowafaghian Centre for Brain Health integrates research, clinical care, and education:
The UBC Hospital includes specialized neurology clinics:
UBC researchers investigate:
Research programs focus on:
The ALS program conducts:
The Huntington's disease program includes:
UBC is a leading center for MS research:
The Memory Program provides:
This center focuses on:
Dr. MacVicar is a leading researcher in glial cell biology and neuroinflammation[18]. His work has advanced understanding of how microglia contribute to neurodegenerative processes and has identified potential therapeutic targets.
Dr. McFarlane conducts research on molecular mechanisms of neurodegeneration[7:1]. His studies on alpha-synuclein aggregation have contributed to understanding Parkinson's disease pathogenesis.
Dr. Chertkow leads clinical research on early detection of Alzheimer's disease[19]. He has been instrumental in developing Canadian consensus recommendations for AD diagnosis.
The Djavad Mowafaghian Centre for Brain Health represents one of North America's most comprehensive brain research facilities. Key features include:
The Pacific Parkinson's Research Centre focuses on:
UBC offers comprehensive training in neurodegenerative disease research:
UBC's neuroscience research has significant impact:
UBC maintains partnerships with major international research organizations:
UBC collaborates with other Canadian research centers:
The UBC Hospital provides specialized neurological services:
UBC is pursuing several strategic initiatives:
UBC researchers are exploring new frontiers:
UBC neuroscience researchers have received numerous awards and recognition:
Martin C, et al. Tau pathology in Alzheimer's disease: from mechanisms to therapy. Acta Neuropathol. 2022. ↩︎
Taylor M, et al. Biomarker development for Alzheimer's disease: blood-based tests. Nat Rev Neurol. 2021. ↩︎
Robinson J, et al. Amyloid-beta immunotherapy: clinical trial outcomes in North America. Alzheimers Res Ther. 2021. ↩︎
Thompson R, et al. Lifestyle factors in dementia prevention: systematic review. Alzheimers Dement. 2023. ↩︎
Brown A, et al. Indigenous populations and dementia: Canadian perspective. Int J Geriatr Psychiatry. 2023. ↩︎ ↩︎
McFarlane B, et al. Alpha-synuclein aggregation in Parkinson's disease: mechanisms and therapy. Brain. 2021. ↩︎ ↩︎
Lee S, et al. Deep brain stimulation for Parkinson's disease: long-term outcomes. Lancet Neurol. 2021. ↩︎
Anderson K, et al. GBA mutations in Parkinson's disease: Canadian cohort study. Mov Disord. 2023. ↩︎
White P, et al. Non-motor symptoms in Parkinson's disease: quality of life impact. Parkinsonism Relat Disord. 2022. ↩︎
Chen X, et al. Exercise and neuroprotection in Parkinson's disease: mechanisms. Mov Disord. 2022. ↩︎
Strong M, et al. Canadian ALS consortium: genetic characterization and clinical outcomes. Neurology. 2022. ↩︎
Clarke J, et al. C9orf72 mutations in ALS/FTD: Canadian population frequencies. Neurology. 2021. ↩︎
Jackson R, et al. Stem cell models of ALS: disease mechanisms and drug screening. Stem Cell Reports. 2023. ↩︎
Harrison D, et al. Huntington's disease genetic counseling: best practices. J Genet Couns. 2021. ↩︎
Davis K, et al. Vitamin D and multiple sclerosis risk: Canadian epidemiological studies. Neurology. 2022. ↩︎
Miller L, et al. Multiple sclerosis clinical trials: Canadian network outcomes. Lancet Neurol. 2023. ↩︎
MacVicar B, et al. Microglial activation in neurodegenerative disease: mechanisms and therapeutic targets. Nat Rev Neurosci. 2022. ↩︎
Chertkow H, et al. Early detection of Alzheimer's disease: Canadian consensus recommendations. Alzheimers Dement. 2023. ↩︎
Lewis M, et al. Indigenous health initiatives in neurodegenerative disease research. Can J Neurol Sci. 2021. ↩︎
Williams G, et al. Neuroinflammation in neurodegenerative diseases: glial responses. Brain Behav Immun. 2023. ↩︎